As the FT notes this morning the Publicis-Omnicom merger has failed. The French-US deal always looked to be tax driven. As the CEO of US partner Omnicom told the FT
the company had accumulated “an awful lot of cash”.
structured so neither company nor its shareholders would incur tax, but the groups faced challenges receiving approval from tax authorities in France, the Netherlands and the UK.
As recently as April, the companies said there was no reason to believe that the deal structure could not be achieved.
Rumours began a while ago that suggested that this was not true and that the expected $80m in annual tax savings the merger had hoped for might not be delivered. From then on the deal seemed on the rocks.
There are lessons in this. As I have said before, tax cannot drive commercial logic. The US corporate tax system is corrosive, as I have also argued, as a result. And here a deal has floundered because a merger driven by tax greed, not commercial necessity or even imperative, has come unstuck.
I hope the markets take note. All those consider the Pfizer deal should smell the coffee.
It would be better still if the US did and took action to reform its tax system.